Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

A2290

Sigma-Aldrich

Anti-Human IgG (γ-chain specific), F(ab′)2 fragment−Peroxidase antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.46

Source biologique

goat

Niveau de qualité

Conjugué

peroxidase conjugate

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

secondary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Espèces réactives

human

Technique(s)

direct ELISA: 1:10,000
western blot: suitable

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Description générale

Human IgGs are glycoprotein antibodies that contain two equivalent light chains and a pair of identical heavy chains. IgGs have four distinct isoforms, ranging from IgG1 to IgG4. These antibodies regulate immunological responses to allergy and pathogenic infections. IgGs have also been implicated in complement fixation and autoimmune disorders . Anti-Human IgG (γ-chain specific), (F(ab′)2) fragment-Peroxidase antibody is specific for human IgG when tested against human IgA, IgG, IgM, Bence Jones κ, and λ myeloma proteins.

Immunogène

Purified human IgG

Application

Anti-Human IgG (γ-chain specific), (F(ab′)2) fragment-Peroxidase antibody is suitable for use in ELISA and western blot .
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Enzyme-linked immunosorbent assay (1 paper)
Peroxidase-conjugated goat anti-human IgG (Fab specific) antibody was used for western blot and ELISA analysis of yeast cultures genetically modified to produced recombinant Fab fragments. Anti-Human IgG antibody was used at a 1:10,000 dilution in PBS and incubated for 1 hour at room temperature. Binding in ELISA assays was detected with a O-phenylene- diamine substrate solution (Sigma).

Forme physique

Solution in 0.01 M phosphate buffered saline, pH 7.4 containing 1% bovine serum albumin with preservative

Notes préparatoires

Prepared using the periodate method described by Wilson, M.B., and Nakane, P.K., in Immunofluorescence and Related Staining Techniques, Elsevier/North Holland Biomedical Press, Amsterdam, p215 (1978).

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Pictogrammes

Exclamation markEnvironment

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Junzo Nojima et al.
Clinical chemistry, 51(3), 545-552 (2005-01-08)
Venous thromboembolic events such as deep vein thrombosis and pulmonary embolism are common manifestations of antiphospholipid syndrome. Our aim was to clarify the roles of anti-phospholipid (aPL) antibodies in the pathogenesis of venous thromboembolism (VTE) in patients with systemic lupus
K Kiernan et al.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 8(9), 1829-1839 (2008-08-02)
Antibodies directed at non-gal xenoantigens are responsible for acute humoral xenograft rejection when gal knockout (GalTKO) pig organs are transplanted into nonhuman primates. We generated IgM and IgG gene libraries using peripheral blood lymphocytes of rhesus monkeys initiating active xenoantibody
Nils Mülling et al.
Infection (2023-05-27)
Vaccination against Streptococcus pneumoniae is recommended in transplant recipients to reduce the morbidity and mortality from invasive pneumococcal disease. Previous studies indicate that transplant recipients can produce specific antibodies after vaccination with the 13-valent pneumococcal conjugate vaccine Prevenar 13 (PCV13)
Joanne L Zahorsky-Reeves et al.
Xenotransplantation, 14(2), 135-144 (2007-03-27)
Recent work has indicated a role for anti-Gal alpha 1-3Gal (Gal) and anti-non-Gal xenoantibodies in the primate humoral rejection response against human-decay accelerating factor (hDAF) transgenic pig organs. Our laboratory has shown that anti-porcine xenograft antibodies in humans and non-human
Philippe Gatault et al.
mAbs, 7(6), 1205-1211 (2015-09-05)
The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic-uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding of eculizumab pharmacokinetics and subsequent individual dose adjustment could reduce this cost. We measured the trough

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique